Literature DB >> 28552366

Amyotrophic lateral sclerosis.

Michael A van Es1, Orla Hardiman2, Adriano Chio3, Ammar Al-Chalabi4, R Jeroen Pasterkamp5, Jan H Veldink1, Leonard H van den Berg6.   

Abstract

Amyotrophic lateral sclerosis is characterised by the progressive loss of motor neurons in the brain and spinal cord. This neurodegenerative syndrome shares pathobiological features with frontotemporal dementia and, indeed, many patients show features of both diseases. Many different genes and pathophysiological processes contribute to the disease, and it will be necessary to understand this heterogeneity to find effective treatments. In this Seminar, we discuss clinical and diagnostic approaches as well as scientific advances in the research fields of genetics, disease modelling, biomarkers, and therapeutic strategies.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28552366     DOI: 10.1016/S0140-6736(17)31287-4

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  256 in total

Review 1.  Biomarkers for neurodegenerative diseases.

Authors:  Oskar Hansson
Journal:  Nat Med       Date:  2021-06-03       Impact factor: 53.440

2.  The Study of Language in the Amyotrophic Lateral Sclerosis - Frontotemporal Spectrum Disorder: a Systematic Review of Findings and New Perspectives.

Authors:  Marta Pinto-Grau; Orla Hardiman; Niall Pender
Journal:  Neuropsychol Rev       Date:  2018-04-28       Impact factor: 7.444

3.  Radial diffusivity as an imaging biomarker for early diagnosis of non-demented amyotrophic lateral sclerosis.

Authors:  Yifang Bao; Liqin Yang; Yan Chen; Biyun Zhang; Haiqing Li; Weijun Tang; Daoying Geng; Yuxin Li
Journal:  Eur Radiol       Date:  2018-06-08       Impact factor: 5.315

4.  Study of occupation and amyotrophic lateral sclerosis in a Danish cohort.

Authors:  Aisha S Dickerson; Johnni Hansen; Marianthi-Anna Kioumourtzoglou; Aaron J Specht; Ole Gredal; Marc G Weisskopf
Journal:  Occup Environ Med       Date:  2018-06-25       Impact factor: 4.402

Review 5.  The Roles of Matrix Metalloproteinases and Their Inhibitors in Human Diseases.

Authors:  Griselda A Cabral-Pacheco; Idalia Garza-Veloz; Claudia Castruita-De la Rosa; Jesús M Ramirez-Acuña; Braulio A Perez-Romero; Jesús F Guerrero-Rodriguez; Nadia Martinez-Avila; Margarita L Martinez-Fierro
Journal:  Int J Mol Sci       Date:  2020-12-20       Impact factor: 5.923

6.  Canadian best practice recommendations for the management of amyotrophic lateral sclerosis.

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

7. 

Authors:  Christen Shoesmith; Agessandro Abrahao; Tim Benstead; Marvin Chum; Nicolas Dupre; Aaron Izenberg; Wendy Johnston; Sanjay Kalra; Desmond Leddin; Colleen O'Connell; Kerri Schellenberg; Anu Tandon; Lorne Zinman
Journal:  CMAJ       Date:  2020-11-16       Impact factor: 8.262

Review 8.  A Quarter Century of APOE and Alzheimer's Disease: Progress to Date and the Path Forward.

Authors:  Michaël E Belloy; Valerio Napolioni; Michael D Greicius
Journal:  Neuron       Date:  2019-03-06       Impact factor: 17.173

Review 9.  The path to biomarker-based diagnostic criteria for the spectrum of neurodegenerative diseases.

Authors:  Filippo Baldacci; Sonia Mazzucchi; Alessandra Della Vecchia; Linda Giampietri; Nicola Giannini; Maya Koronyo-Hamaoui; Roberto Ceravolo; Gabriele Siciliano; Ubaldo Bonuccelli; Fanny M Elahi; Andrea Vergallo; Simone Lista; Filippo Sean Giorgi; Harald Hampel
Journal:  Expert Rev Mol Diagn       Date:  2020-02-27       Impact factor: 5.225

10.  CMAP decrement by low-frequency repetitive nerve stimulation in different hand muscles of ALS patients.

Authors:  Dong Zhang; Yuying Zhao; Chuanzhu Yan; Lili Cao; Wei Li
Journal:  Neurol Sci       Date:  2019-08-03       Impact factor: 3.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.